Zum Inhalt springen

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of updated data from the completed dose escalation part and first data from the ongoing expansion part of Study 1100, a US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) at the 2024 Annual Meeting of the American Society for Clinical Oncology. The data will be presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, during a poster presentation session that begins at 10:00 AM EDT / 4:00 PM CEST on Sunday, June 2nd, 2024. NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for… 

more »NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program

Risikobewertung gentechnisch veränderter RNAi-Pflanzen unzureichend

Gentechnisch veränderte Pflanzen (GMPs), die auf den Markt gebracht werden sollen, können so gestaltet werden, dass sie durch RNA-Interferenz (RNAi) eine „Gen-Stilllegung“ bewirken. Die Risiken für den Menschen sind dabei weitgehend nicht untersucht. Die Europäische Behörde für Lebensmittelsicherheit (EFSA) und andere internationale Risikobewertungsstellen/Regulierungsbehörden haben mehrere Maßnahmen ergriffen, um festzustellen, ob die bestehenden Risikobewertungsansätze für GMPs für die Risikobewertung von RNAi-basierten GMPs geeignet sind oder ergänzende oder alternative Ansätze erfordern. Unseres Wissens wurden auf internationaler Ebene keine speziellen Richtlinien für die Risikobewertung und Regulierung von RNAi-basierten GMPs entwickelt, was bestätigt, dass bestehende wissenschaftlich fundierte Risikobewertungsansätze für GMPs im Allgemeinen als für RNAi-basierte GMPs geeignet angesehen werden. Für die Risikobewertung von RNAi-basierten GMPs wurden jedoch einige Besonderheiten festgestellt. In dieser Studie berichten Forscher über einige dieser Besonderheiten, die vom GMO-Gremium der EFSA für die molekulare Charakterisierung, die Bewertung der Lebensmittel-/Futtermittelsicherheit und die… 

more »Risikobewertung gentechnisch veränderter RNAi-Pflanzen unzureichend

Dyne Therapeutics Announces Closing of Public Offering of Common Stock

Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $374.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne. Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Johnson & Johnson to Acquire Yellow Jersey Therapeutics Including Rights to NM26

Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis

Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003

Aummune, a clinical-stage biopharmaceutical company developing a unique class of oligonucleotide drugs to treat solid tumors, announced today that an abstract of the Company’s Phase 1 trial of its proprietary, investigational product AM003 will be presented on June 1, 2024, at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) taking place in Chicago, Illinois. Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has entered into a definitive agreement for the sale and issuance of 1,898,734 shares of the Company’s common stock and warrants to purchase up to 1,898,734 shares of common stock at a combined offering price of $1.58 per share of common stock and accompanying warrant in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $1.455 per share, will be immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about May 29, 2024, subject to the satisfaction of customary closing conditions. Reviva… 

more »Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event

Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Peter M. Carlson, Chief Executive Officer of Spectral AI, is scheduled to participate in a fireside chat at Benzinga’s “AI Unleashed: Exploring the Possibilities” virtual event, taking place on May 30, 2024. Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event

Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain

In a recent clinical study, Precision recorded human brain activity from over four thousand electrodes, allowing streaming of real-time cortical data for visualization of brain activity In a recent clinical study, Precision recorded human brain activity from over four thousand electrodes, allowing streaming of real-time cortical data for visualization of brain activity Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain

Breite Kritik an Lauterbach wegen Verschiebung von Pflegereform

Die Ankündigung von Bundesgesundheitsminister Karl Lauterbach (SPD), seine geplante Finanzierungsreform der Pflegeversicherung voraussichtlich in der laufenden Wahlperiode nicht mehr umzusetzen, stößt auf breite Kritik. „Die Pflegesituation und ihre Finanzierung werden sich weiter zuspitzen, wenn wir jetzt nichts tun“, sagte Jens Teutrine, pflegepolitischer Sprecher der FDP-Bundestagsfraktion, der „Welt“. „Es braucht mehr pragmatischen Reformwillen statt ideologischer Ablenkungsmanöver. […] Breite Kritik an Lauterbach wegen Verschiebung von Pflegereform

Cowzdrowiu – HPV-DNA-Tests im Leistungspaket, Medikamente gegen RA und seltene Krankheiten

Zwei Treffen in einer Woche, darunter: die seit langem postulierte Aufnahme von HPV-DNA-Tests in das Leistungspaket zur Vorbeugung von Gebärmutterhalskrebs und zur Bewertung von Arzneimitteln, unter anderem für RA, viele Medikamente für Kinder, einschließlich Bluthochdruck und Therapien für seltene Krankheiten – das hat der bei AOTMiT tätige… Cowzdrowiu – HPV-DNA-Tests im Leistungspaket, Medikamente gegen RA und seltene Krankheiten